Herceptin shows biosimilar markets can work. To what extent

Copycat versions of branded cancer drug Herceptin led to lower biologic prices, yet the real test for biosimilars lies ahead.

Related Keywords

Abbvie Humira , Johnson Remicade , Alice Chen , Amgen Kanjinti , Peter Bach , Health Affairs , Leonardd Schaeffer Center , Association Of Accessible Medicines , Amgen , Drug Administration , Southern California , Sol Price School , Public Policy , Health Policy , Accessible Medicines ,